Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Symposium

[Free Online Symposium] Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks


Speakers: Borje Darpo (ERT), Jay Mason (Spaulding Clinical), Anne Bonneville (Terns Pharmaceuticals), Lauren Lohmer (Nuventra), Yehong Wang (Genentech)
Organizers: Peter Staehr (ChemoCentryx), Snow Ge (Nektar), Kelly Gelinne (Nuventra) and Ginny Schmith (Nuventra)
Date: 2021-03-23- 03/24/2021
Time: 8:30-12:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (1)Altasciences;(Major Sponsorship - Day 2 still open)
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-03-20  (it will close sooner if the seating cap is reached)

About the Topic

In an effort to reduce risk to patients, regulatory agencies now require rigorous analysis of QT intervals in clinical trials as a measure of drug safety. This seminar will discuss the various ways to evaluate cardiac safety using a variety of methods - as early as preclinical and throughout your clinical trials.

Symposium Agenda – Day 1: March 23, 2021 (Times listed for Pacific Time (PT) and Eastern Time (ET))

8:30-8:45 PT / 11:30-11:45 ET: PBSS Welcome and Introductions – Shichang Miao, PBSS President

8:45-9:30 PT / 11:45-12:30 ET: State-of-the-Art: TQT studies (QT and C-QT Analyses, Challenges & Examples) - Borje Darpo (ERT)

9:30-10:15 PT / 12:30-1:15 ET: Non-clinical aspects related to the ICH Q&A - Anne Bonneville (Terns Pharmaceuticals) 

10:15-10:25 PT / 1:15-1:25 ET: AltaSciences – Major Sponsor Presentation

10:25-10:40 PT / 1:25-1:40 ET: Break

10:40-11:25 PT / 1:40-2:25 ET: Case Study - Biologics C-QT project supporting a major readout - Yehong Wang (Genentech)

11:25 -12:10 PT / 2:25-3:10 ET: Panel Discussion Day 1 (All speakers, moderated by Ginny Schmith)

 

Symposium Agenda – Day 2: March 24, 2021 (Times listed for Pacific Time (PT) and Eastern Time (ET))

8:30-8:45 PT / 11:30-11:45 ET: Introductions

8:45-9:30 PT / 11:45-12:30 ET: Cardiac safety and TQT waivers (Waiver pathways, ECG acquisition requirements) - Jay Mason (Spaulding)

9:30-10:15 PT / 12:30-1:15 ET: Wide Confidence Intervals with a Non-Positive Concentration-Related Slope: Implications from the White Paper - Lauren Lohmer (Nuventra)

10:15-10:30 PT / 1:15-1:30 ET: Break

10:30-11:15 PT / 1:30-2:15 ET: Evaluating QT Changes in the Presence of HR Changes - Lars Johannesen (FDA)

11:15 -12:00 PT / 2:15-3:00 ET: Panel Discussion Day 2 (All speakers except Yehong Wang, moderated by Ginny Schmith)


About the Speakers

Click to Enter Answer Explanations.


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/28/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad